Recent Updates — CV
CapsoVision, Inc. announced that its AI Highlights feature for the CapsoCam Plus system received U.S. Food and Drug Administration clearance on September 25, 2026. The AI-assisted reading tool is designed to support physicians in reviewing small bowel capsule endoscopy studies by recognizing and marking suspected abnormal lesions, thereby reducing review time. This regulatory milestone follows the international launch of the feature earlier in the year. CapsoVision operates as a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions for gastrointestinal disease detection.
CapsoVision, Inc. entered into a securities purchase agreement on September 17, 2026, for a registered direct offering of 3,163,444 shares of common stock at $5.69 per share. The transaction generates approximately $18 million in gross proceeds before expenses. Investors include Star One Global Capital Limited (purchasing ~$5.0 million) and Eliyahou Harari (~$10.0 million), both related persons owning over 5% of the company, along with another existing stockholder (~$3.0 million). The shares were sold without an underwriter or placement agent at a 5% discount to the September 16 closing price. Closing is expected on September 18, 2026, subject to customary conditions. Proceeds will fund general corporate purposes including sales, marketing, R&D, and working capital.
CapsoVision operates in the semiconductor industry, specializing in hyperspectral imaging technology.
CapsoVision, Inc. entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. on August 13, 2026, establishing an at-the-market offering program allowing the company to sell up to $100 million of its common stock at its sole discretion. The company simultaneously filed a Registration Statement on Form S-3 (File No. 333-298315) with the SEC to facilitate these potential equity issuances. CapsoVision, Inc. operates in the technology sector, specializing in computer vision and artificial intelligence solutions for industrial automation.
CapsoVision reported second quarter 2026 revenue of $3.6 million, a 10% increase year-over-year, driven by a 13% rise in capsule sales offset by a 3% decline in average selling price. Gross profit was $1.9 million with a 51% margin, while operating expenses rose to $9.5 million due to clinical trial and development costs. The company holds $9.1 million in cash and announced the international launch of its AI Highlights feature, anticipating FDA clearance by late Q3 2026. Additionally, CapsoVision entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald for an at-the-market program allowing up to $100 million in common stock sales. The company operates in the medical technology industry, developing advanced imaging and AI-enabled capsule endoscopy solutions.
CapsoVision, Inc. announced on July 1, 2026, that Dr. David S. Shields was appointed as a Class I director and member of the Compensation Committee, filling the vacancy left by Dr. Joanne Imperial. Dr. Shields, a board-certified gastroenterologist, entered into a consulting agreement to provide services at $600 per hour for up to 3 hours per week. Dr. Imperial resigned from the Board effective immediately but will continue as an independent consultant under an amended agreement earning $600 per hour for up to 5 hours per week, which includes a 10,000-share stock option grant. CapsoVision, Inc. is a medical technology company specializing in capsule endoscopy.